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Thirteen bovine leukemia virus- (BLV-) negative and 22 BLV-positive Holstein cows were immunized with J5 Escherichia coli
bacterin at dry oﬀ, three weeks before calving, during the second week after calving, andthree weeks after the third immunization.
Serumwascollected beforetheinitialimmunization,immediatelybeforethethirdandfourthimmunizations,and21daysafterthe
fourth immunization.Anti-J5 E. coli IgM, IgG1, and IgG2 titers were determined by ELISA. Anti-J5 E. coli IgM titers did notdiﬀer
signiﬁcantly (P = .98) between groups. Increases in anti-J5 E. coli IgG1 titers were higher in the BLV-negative cows (P = .057).
Geometric mean anti-J5 E. coli IgG2 titers increased fourfold in the BLV-negative cows, which was signiﬁcantly higher (P = .007)
than the twofold increase in the BLV-positive cows. Cattle infected with BLV may have impaired serologic responses following
immunizationwith J5 bacterin, and response may diﬀer according to antibody isotype.
1.Introduction
Enzootic bovine leukosis is a contagious disease of cattle
induced by an exogenous retrovirus, bovine leukemia virus
(BLV). The disease complex is characterized by a persistent
lymphocytosis which can culminate in B cell lymphoma
[1]. The National Animal Health Monitoring System Dairy
(NAHMS)1996 study revealed that BLV is present in 89% of
US dairy operations [2]. Most infected cows do not display
outward signs of disease, and these animals are referred to as
asymptomatic or aleukemic. Approximately 30–40% of BLV
carriers will develop a persistent lymphocytosis, while fewer
than 5% develop malignant lymphosarcoma [1].
The progression of BLV is known to aﬀect host defense
mechanisms. Although BLV is associated mainly with infec-
tions of B lymphocytes, BLV provirus has been detected in
the DNA of immunoaﬃnity puriﬁed T lymphocytes from
BLV-infected cattle [3]. There is a dramatic increase in B
lymphocyte populations with decreases in the percentages of
bothCD4+ andCD8+ Tlymphocytepopulations[4].Certain
type 1 cytokines from CD4+ T lymphocytes, including
interleukin-2 (IL2), IL12, and interferon gamma (IFNγ), are
reduced during BLV infections, and this altered cytokine
production was suggested to be responsible for suppressed
mitogen-induced T lymphocyte proliferation [4–6]. BLV
infection may suppress T-cell apoptosis and gene expres-
sion of proteins important in the apoptotic pathway [7].
Considering the critical role that T- and B-cell populations
play in humoral immunity, the purpose of this study was to
investigate the eﬀect of BLV on the serologic response to an
Escherichia coli bacterin that is commonly administered in
dairy cattle.
2.Materialsand Methods
2.1. Animal Selection and Care. Forty-four Holstein cows
completing their ﬁrst or greater lactation and starting their
dryperiodwereenrollediftheherdmanagerdeterminedthat
the cows were healthy on the basis of a physical examination
(appetite, attitude, milk production, and lack of clinical2 Veterinary Medicine International
mastitis). The mean length of the dry period for enrolled
cows was 61 days, with a range of 53 to 68 days. A sample
of blood was collected from each cow, immediately before
immunization with J5 bacterin. Subsequent to the results
of ELISA serology (Diagnostic Center for Population and
Animal Health, Michigan State University), 24 BLV-positive
(BLV POS) and 20 BLV-negative (BLV NEG) cows were
identiﬁed for continuing in the study. However, 2 cows
from both groups were prematurely culled before the end
of the trial and were, therefore, excluded from our study.
Additionally, 2 BLV NEG cows seroconverted from negative
to positive BLV status during the course of the trial, 1 BLV
NEG cow acquired a case of clinical coliform mastitis, which
was considered to likely aﬀect her anti-J5 antibody response,
and 2 additional BLV NEG cows were withdrawn from the
immunization schedule after parturition because of compli-
cations associated with twinning. Thus, after exclusions, 35
animals remained onthe trial, 22BLVPOSand 13BLV NEG.
All cows enrolled in the study were housed at the Kellogg
Biological Station Dairy at Michigan State University, were
milked 3times/d, and had unlimited access to water and a
total mixed ration. The study protocol was approved by the
Institutional Animal Care and Use Committee.
2.2. Vaccination Schedule. Cows were administered a 5-mL
dose of a commercial J5 Escherichia coli bacterin (J5 E.
coli Bacterin, Pﬁzer Animal Health, Kalamazoo, Michigan,
USA) by subcutaneous injection on the last day of lactation
(approximately 7 weeks before parturition) and, subse-
quently, 3 weeks before parturition, the second week after
parturition (between 8 and 14 days after parturition), and
between 29 and 35 days after parturition. The ﬁrst and third
doses were administered subcutaneously in the left side of
the neck, and the second and fourth doses were given on the
right side of the neck.
2.3. Blood Collection Schedule. Blood samples were collected
from the coccygeal vein into 15-mL sterile glass tubes,
allowed to clot overnight at 4◦C, and then centrifuged at
1,500×gf o r1 5m i n u t e sa t4 ◦C. Serum was harvested and
stored in 3-mL aliquots at −20◦C until assayed by ELISA for
anti-J5 E. coli antibody titers. Blood samples were collected
immediately before the ﬁrst immunization and before the
third, fourth, and 21 days after the fourth immunization.
2.4. Preparation of J5 E. coli Whole-Cell Antigen for ELISA.
Isolated colonies from pure cultures of J5 E. coli were
used to inoculate trypticase soy broth, which was incubated
with shaking at 120rounds/min for 18 hours at 37◦C. The
bacterial culture was checked for purity; then, 99% phenol
was added and the solution was shaken for 1 hour at
120rpm at 37◦C. The phenol-killed whole-cell bacteria were
centrifuged at 1,000×gf o r1 2m i n u t e sa t4 ◦C; the pellet
was washed twice and centrifuged in 500mL of sterile 0.9%
NaClsolution.Afterthe secondcentrifugation, thepellet was
suspended in sterile PBS solution to attain a concentration
of approximately (1 × 1011 CFU/mL) as determined from
quantitative count of bacterial growth from serial dilutions.
The whole-cell J5 antigen solution was stored in 5-mL
aliquots at −80◦C until used in the ELISA. ELISA plates
were prepared by diluting the antigen 1:250 in sodium
carbonate/bicarbonate buﬀer (pH 9.6) and adding 100μL
to each well of a 96-well ﬂat bottom plate. Prepared plates
were then incubated overnight in an ambient air incubator
at 37◦C.
2.5. ELISA to Determine Anti-J5 E. coli Antibody Titers.
Serum anti-J5 E. coli titers were determined by modiﬁcation
of an ELISA protocol as described by Tyler et al. [8].
The antigen was phenol-killed whole-cell J5 E. coli,t h e
detection antibody was horseradish peroxidase-conjugated
sheep antibovine IgG1, IgG2, or IgM (Bethyl Laboratories,
Montgomery, Texas, USA), each diluted 1:25,000 in sample
diluent, and the substrate was hydrogen peroxide-azino-
bis-3-ethylbenzthiazoline sulfonic acid. The assay positive
control sample was pooled sera collected from steers hyper-
immunized by administration of J5 E. coli bacterin [9], and
the negative control sample was fetal bovine serum (Life
Technologies, Rockville, Maryland, USA). Following antigen
incubation, plates were washed twice with 250μLo fac o m -
mercial wash solution (KPL, Inc., Gaithersburg, Maryland,
USA) and 200μL of a blocking-diluent solution (0.2M Tris,
0.3% Tween-20, and 1% ovalbumin) was added. Plates were
then incubated for one hour in an ambient air incubator at
37◦C. Wells were again washed twice and 200μL of test sera
were diluted serially, in duplicate, by three fold dilutions for
each descendingrow,and platesincubatedforonehourinan
ambient air incubator at 37◦C. For IgG2 and IgM ELISA, the
initial dilutionofsera was1:67,with dilutionsofsubsequent
rows of 1:200; 1:600; 1:1,800; 1:5,400; 1:16,200; and
1:48,600.BecauseofhigherconcentrationsofIgG1inserum
relative to the other isotypes, the initial dilution of sera for
IgG1 ELISA was 1:600, with dilutions of subsequent rows
of 1:1,800; 1:5,400; 1:16,200; and 1:48,600; 1:145,800;
and 1:437,400. Plates were washed ﬁve times after sera
incubation, 100μL of diluted conjugate antibody was added
and again incubated for one hour. Plates were washed once
more for ﬁve times, 100μL of substrate was added, and after
25 minutes of room temperature incubation in the dark, the
reaction was stopped with 100μLof1%SDS.Optical density
was determined by dual-wavelength spectrometric analysis
(405nm for test and control samples, after normalization
of the entire plate at 450nm on the basis of blank wells
containing only diluent) by use of an ELISA plate reader
(SpectraMax 190, Molecular Devices, Sunnyvale, California,
USA). Thus, normalized optical densities at 405nm were
the ﬁnal data set for the statistical analysis. In order to
reduce variation associated with daily changes in laboratory
environment, titers for each immunoglobulin isotype (IgM,
IgG1, and IgG2) were determined for the entire collection of
serum samples (all cows, all serial samples per cow) on one
day. Repetitions of each serum sample titer, as determined
by ELISA, that had a coeﬃcient of variation of ≥15% were
repeated.
2.6. ELISA to Determine BLV Antibody. Antibodies to BLV-
glycoprotein 51 (gp51) in bovine sera were detected by
a commercial ELISA (VMRD Inc., Pullman, Washington,Veterinary Medicine International 3
USA)performed attheDiagnosticCenterforPopulationand
Animal Health, Michigan State University. Brieﬂy, sample
serum antibodies bind to BLV gp51 molecules attached to
the plastic wells of the microtiter plate. Binding of these
serum antibodies is detected by reaction with horseradish
peroxidase- (HRP-) labeled aﬃnity-puriﬁed goat antibodies
to bovine immunoglobulins. Attached HRP-labeled anti-
bodies are detected by addition of enzyme substrate and
quantitated by subsequent blue color product development.
Strong color developmentindicates the presence of antibody
to BLV gp51 in the sample serum. Very weak or no color
development indicates the absence of antibody to BLV gp51
in the sample serum.
2.7. Statistical Analyses. T h eb a s e l i n ep r e - v a c c i n a t i o nI g G 1 ,
IgG2 and IgM titers for the J5 antigen were subtracted
from each of the corresponding repeated postvaccination
measurementstodeterminethechangeintiterforeachofthe
threerepeated postvaccination measurements. The increases
in serum titers (log10) between each serum collection time
period were used as the repeated dependent variable in
repeated measures ANOVA models (SAS Proc GLM (SAS-
Institute, Cary, North Carolina, USA)). The sphericity test
for orthogonal components was used to indicate if any
assumptions of the statistical model had been severely
violated [10].
3.Results
3.1. IgM. Geometric mean IgM titers increased from 3,250
at the time of the ﬁrst immunization to 4,100 at 21 days after
the fourth immunization in the BLV NEG cows and from
2,900to4,100fortheBLVPOScows(Figure 1).Therepeated
measures ANOVA indicated no overall signiﬁcant diﬀerence
in titer change between the BLV NEG and BLV POS cows
(P = .90). The eﬀect of BLV infection was not signiﬁcant at
P>. 66atall threeoftherepeatedtimepoints. Thesphericity
test for orthogonal components was P = .12, suggesting that
the model was valid.
3.2. IgG1. Anti-J5 E. coli IgG1 titers increased in all 13 BLV
NEGcowsat21daysafterthethirdandfourthimmunization
and 19/22 (86.4%) and 20/22 (90.9%) BLV POS cows 21
days after the third and fourth immunization, respectively.
Geometric mean IgG1 titers increased from 3,700 at the
time of the ﬁrst immunization to 32,500 at 21 days after the
fourth immunization in the BLV NEG cows, and from 5,300
to 27,500 for the BLV POS cows (Figure 2). The repeated
measures ANOVA indicated a nearly signiﬁcant diﬀerence
in overall titer change between the BLV NEG and BLV POS
cows (P = .057). The eﬀect of BLV infection was at P = .22
at the ﬁrst repeated measure, P = .085 at the second time
point, and P = .14 at the time of the last repeated measure.
However, the sphericity test for orthogonal components was
P<. 0001, suggesting that the model assumptions may have
been violated.
3.3. IgG2. Anti-J5 E. coli IgG2 titers increased in 12/13
(92.3%) and 13/13 (100%) BLV NEG cows at 21 days after
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Figure 1: Mean ± SEM serum IgM titers in 22 BLV-positive cows
(BLV POS) and 13 BLV-negative cows (BLV NEG) administered a
J5 E. coli bacterin with 4 doses of bacterin administered SC in the
left side of the neck (odd numbered doses) or right side of the neck
(evennumbered doses).Bloodsamples were collected fromallcows
atthetimeoftheﬁrst(V1:approx7 weeksbefore parturition),third
(V3: second week after parturition (between days 8 and 14 after
parturition)), fourth (V4: 5 weeks (between 29 and 35 days) after
parturition) vaccinations,and 21 days after the fourth vaccination.
the third and fourth immunization, respectively, and 13/22
(59.1%) and 15/22 (68.2%) BLV POS cows 21 days after the
thirdandfourthimmunizations.GeometricmeanIgG2titers
increased from 1,045 at the time of the ﬁrst immunization
to 4,200 at 21 days after the fourth immunization in the
BLV NEG cows, and from 1,450 to 2,900 for the BLV POS
cows (Figure 3). The repeated measures ANOVA indicated
an overall signiﬁcant diﬀerence in titer change between the
BLV NEG and BLV POS cows at P = .0072. The eﬀect of BLV
infection was signiﬁcant at P = .0045 at the ﬁrst repeated
measure, P = .034 at the second repeated measure, and P =
.024 at the time of the last repeated measure. The sphericity
test for orthogonal componentswas P<. 025,indicating that
the model ﬁt was acceptable.
4.Discussion
Numerous studies have determined that vaccination with J5
bacterin increases anti-J5 E. coli immunoglobulin, especially
G1 and G2 isotypes, in serum and milk as compared
to unvaccinated controls [11–14]. Additionally, the use of
multiple doses of J5 bacterin (hyperimmunization), such as
used in this study, increases the serum antibody response
and has been associated with decreasing incidence of severe
coliform mastitis compared to more traditional three-dose
regimens [15]. In the present study, serum IgM titers only
modestly increased over the course of the trial in both
groups of cows. This is similar to results obtained in a
recent New York study that determined serum IgM response
did not increase following a two-dose J5 bacterin regimen,
although IgG1 and IgG2 responses did increase [14]. Earlier
studies suggested that serum IgM increases in response to J5
immunization [9, 12]. IgG2 and IgG1 have been identiﬁed4 Veterinary Medicine International
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Figure 2: Mean ± SEM serum IgG1 titers in 22 BLV-positive cows
(BLV POS) and 13 BLV-negative cows (BLV NEG) administered a
J5 E. coli bacterin with 4 doses of bacterin administered SC in the
left side of the neck (odd-numbered doses) or right side of the neck
(even-numbered doses).Bloodsampleswere collected fromallcows
atthetimeoftheﬁrst(V1:approx7weeks beforeparturition), third
(V3: second week after parturition (between days 8 and 14 after
parturition)), fourth (V4: 5 weeks (between 29 and 35 days) after
parturition) vaccinations, and 21 days after the fourth vaccination.
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Figure 3: Mean ± SEM serum IgG2 titers in 22 BLV-positive cows
(BLV POS) and 13 BLV-negative cows (BLV NEG) administered a
J5 E. coli bacterin with 4 doses of bacterin administered SC in the
left side of the neck (odd-numbered doses) or right side of the neck
(even-numbered doses).Bloodsampleswere collected fromallcows
atthetimeoftheﬁrst(V1:approx7weeks beforeparturition), third
(V3: second week after parturition (between days 8 and 14 after
parturition)), fourth (V4: 5 weeks (between 29 and 35 days) after
parturition) vaccinations, and 21 days after the fourth vaccination.
∗Within a time point, mean values for groups diﬀer signiﬁcantly
(P<. 05).
as critical for mammary gland defense during infection
although IgM and IgG2 promote phagocyte opsonization
and ensuing phagocytosis of mastitis-causing pathogens
[16]. Hyperimmunization with J5 bacterin induced recogni-
tion of proteins, derived from J5 E. coli whole cell lysates, by
IgG2 that were not recognized by other isotypes [9].
We determined that anti-J5 IgG1 and IgG2 titers
increased in both groups of cows following three and four
doses of the bacterin. However, the increase in IgG1 titers
tended to be higher in the NEG cows, and the increase in
IgG2titers,inparticular,weresigniﬁcantlyhigherintheNEG
cows. Thus, our data suggests that BLV infection in dairy
cattle may decrease the antibody response to immunization.
Whereas the presence of J5 E. coli antibodies in serum have
beenassociatedwithprotectionagainst coliformmastitis, the
eﬀects of BLV on resistance to mastitis remain speculative.
Therefore, broad extrapolations concerning BLV status, the
eﬃcacy of J5 vaccination, and mastitis resistance should not
be made from this single descriptive study. Additionally, the
immunization of the cattle in this trial occurred during late
pregnancy and the periparturient period, a stage of lactation
when the immune system is impaired [17]. What eﬀects BLV
may have on vaccine responsiveness in cattle in diﬀerent
physiological states is unknown.
BLV infection reduces expression of type 1 cytokines
from CD4+ T lymphocytes, including interleukin-2 (IL2),
IL12, and interferon gamma (IFNγ)[ 4–6]. Additionally,
cytokine proﬁles from all peripheral blood mononuclear
cell populations, including B lymphocytes, suggest that both
type I and II cytokines are altered with increases in IL10
and IL4, and decreases in IL2, IL12, and IFNγ [5, 17]. The
progression of BLV is also known to disrupt the homeostasis
of lymphocyte proliferation and cell death, in both B-cells
and T-cells [4, 6, 8]. These BLV-induced mechanisms may
play a role on the homeostasis of lymphocyte populations,
have a detrimental impact on the ability of cattle to resist
the progression of infectious disease [5, 8, 18], or as in our
study, response to an adjuvated vaccine. An issue raised
by our results is whether BLV infection may interfere with
the immunogenicity of other vaccine antigens. A previous
report suggested a possible impairment of rotaviral immune
responses in BLV-positive animals [19].
This study was limited in the number of enrolled
animals and in that they were obtained from only one herd.
Although the same standard of determining BLV infection
status (ELISA) was employed for both treatment groups,
the slow development of the disease, and the relatively long
duration of animals in the trial, may have contributed to
variability in our results if cows were falsely identiﬁed as to
BLV status. Previous research determined that PCR assays
for BLV detected new infections in 5 of 8 experimentally
challenged calves more quickly than ELISA although the
ELISA determined infection more readily in 2 of 8 calves,
thus resulting in a nonsigniﬁcant diﬀerence [20]. A study
incorporating a large population of cattle to determine the
relative sensitivity and speciﬁcity of the ELISA to detect
BLV antibodies relative to detecting BLV by PCR has not
been reported. Thus, the BLV antibody ELISA remains a
commonly used diagnostic tool to determine BLV status.
It is not known from this trial what eﬀect BLV might
have on immunization with other commonly used vaccines,
nor on cell-mediated responses following immunization.
Additionally, the stage of infection with regard to persistent
lymphocytosis, and other pathological ﬁndings associated
with BLV infection, were not determined in this study.Veterinary Medicine International 5
Previous research indicated that changes in lymphocyte
proliferation and/or apoptosis will depend on the stage of
BLV infection [8].
5.Conclusions
Dairy cows that were infected with BLV had decreased anti-
body responses to J5 E. coli bacterin as compared to nonin-
fected cows. This is consistent with reports that BLV induces
changes in the complex balance of cytokine expression,
cell proliferation, and programmed death in both T- and
B-lymphocytes, which is critical for immune competence
and eﬀective response to infectious challenge. Although
lymphosarcoma occurs in only a small proportion of dairy
cattle infected with BLV, the virus may have broader, if
not more subtle eﬀects, on the health of dairy cattle. This
potential relationship, and the eﬀect that control of this
disease mayhaveonvaccination programs, shouldbefurther
evaluated.
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